文献速递心脑血管急症

一线降压药类综合比较有效性与安全性的系统 multinational 大规模分析

Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis.
PubMed 文献 · Lancet · 2019-10-24
一句话结论在4.9百万高血压患者中,噻嗪或噻嗪样利尿剂作为初始单药治疗在主要有效性终点上优于ACE抑制剂,而非二氢吡啶类钙通道阻滞剂显著劣于其他四类。

该研究采用新用户队列设计,在全球6个行政索赔数据库和3个电子健康记录数据库中,比较一线降压药类(噻嗪或噻嗪样利尿剂、ACE抑制剂、血管紧张素受体阻滞剂、二氢吡啶类钙通道阻滞剂、非二氢吡啶类钙通道阻滞剂)作为初始单药治疗的有效性与安全性。纳入4.9百万患者,生成22 000个倾向评分校正的风险比。多数估计显示药类间无有效性差异,但噻嗪或噻嗪样利尿剂较ACE抑制剂在急性心肌梗死(HR 0.84,95%CI 0.75-0.95)、心力衰竭住院(0.83,0.74-0.95)和卒中(0.83,0.74-0.95)风险上更优,安全性也更好;非二氢吡啶类钙通道阻滞剂显著劣于其他四类。作者认为该框架支持药类间等效性(与现行指南一致),但噻嗪或噻嗪样利尿剂优于ACE抑制剂、非二氢吡啶类钙通道阻滞剂劣于其他类为例外。

要点

  • 在无合并症指示的高血压初始单药治疗中,噻嗪或噻嗪样利尿剂较ACE抑制剂降低急性心肌梗死风险(HR 0.84,95%CI 0.75-0.95)、心力衰竭住院风险(0.83,0.74-0.95)和卒中风险(0.83,0.74-0.95)。
  • 噻嗪或噻嗪样利尿剂的安全性特征也优于ACE抑制剂。
  • 非二氢吡啶类钙通道阻滞剂作为初始单药治疗显著劣于其他四类一线药物。
  • 多数一线降压药类之间在主要有效性终点上无差异,支持现行指南关于药类等效性的推荐。
  • 该分析基于4.9百万患者、全球6个行政索赔和3个电子健康记录数据库,生成22 000个倾向评分校正的风险比。

适用人群与场景

  • 高血压患者,接受一线降压药类作为初始单药治疗,无合并症指示。

研究设计与关键结果

  • 研究类型:系统、大规模新用户队列研究,使用6个行政索赔数据库和3个电子健康记录数据库,纳入4.9百万患者。
  • 主要有效性终点:噻嗪或噻嗪样利尿剂 vs ACE抑制剂:急性心肌梗死 HR 0.84(95%CI 0.75-0.95),心力衰竭住院 HR 0.83(0.74-0.95),卒中 HR 0.83(0.74-0.95),均支持噻嗪或噻嗪样利尿剂更优。
  • 安全性:噻嗪或噻嗪样利尿剂的安全性特征也优于ACE抑制剂。
  • 非二氢吡啶类钙通道阻滞剂显著劣于其他四类一线药物。
  • 多数药类间比较未显示有效性差异。

证据类型、等级与局限

  • 证据类型:观察性研究(新用户队列设计),系统、大规模分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,该研究支持一线降压药类间在初始单药治疗中的等效性(与现行指南一致),但噻嗪或噻嗪样利尿剂优于ACE抑制剂、非二氢吡啶类钙通道阻滞剂劣于其他类为例外。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Uncertainty remains about the optimal monotherapy for hypertension, with current guidelines recommending any primary agent among the first-line drug classes thiazide or thiazide-like diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel blockers, and non-dihydropyridine calcium channel blockers, in the absence of comorbid indications. Randomised trials have not further refined this choice.

METHODS: We developed a comprehensive framework for real-world evidence that enables comparative effectiveness and safety evaluation across many drugs and outcomes from observational data encompassing millions of patients, while minimising inherent bias. Using this framework, we did a systematic, large-scale study under a new-user cohort design to estimate the relative risks of three primary (acute myocardial infarction, hospitalisation for heart failure, and stroke) and six secondary effectiveness and 46 safety outcomes comparing all first-line classes across a global network of six administrative claims and three electronic health record databases. The framework addressed residual confounding, publication bias, and p-hacking using large-scale propensity adjustment, a large set of control outcomes, and full disclosure of hypotheses tested.

FINDINGS: Using 4·9 million patients, we generated 22 000 calibrated, propensity-score-adjusted hazard ratios (HRs) comparing all classes and outcomes across databases. Most estimates revealed no effectiveness differences between classes; however, thiazide or thiazide-like diuretics showed better primary effectiveness than angiotensin-converting enzyme inhibitors: acute myocardial infarction (HR 0·84, 95% CI 0·75-0·95), hospitalisation for heart failure (0·83, 0·74-0·95), and stroke (0·83, 0·74-0·95) risk while on initial treatment. Safety profiles also favoured thiazide or thiazide-like diuretics over angiotensin-converting enzyme inhibitors. The non-dihydropyridine calcium channel blockers were significantly inferior to the other four classes.

INTERPRETATION: This comprehensive framework introduces a new way of doing observational health-care science at scale. The approach supports equivalence between drug classes for initiating monotherapy for hypertension-in keeping with current guidelines, with the exception of thiazide or thiazide-like diuretics superiority to angiotensin-converting enzyme inhibitors and the inferiority of non-dihydropyridine calcium channel blockers.

FUNDING: US National Science Foundation, US National Institutes of Health, Janssen Research & Development, IQVIA, South Korean Ministry of Health & Welfare, Australian National Health and Medical Research Council.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Suchard MA, Schuemie MJ, Krumholz HM, et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019. PMID: 31668726. doi:10.1016/S0140-6736(19)32317-7

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。